ProSomnus is the first manufacturer of mass-customized Precision Oral Appliance Therapy (OAT) devices to treat OSA. The company has built momentum since its public debut in December 2022, with record revenues and year-over-year revenue growth exceeding 50% in Q1 2023. ProSomnus devices are non-invasive, patient preferred and easy to use, with demonstrated excellent efficacy, safety, adherence, and overall outcomes in a growing body of clinical investigations.
Cyborg Score Rationale
ProSomnus operates in a high-growth market with strong clinical validation and compelling patient advantages over CPAP. However, the company faces execution risks, significant capital needs, and operates in a competitive landscape. Early public-market performance data shows volatility.
Top Insights
Massive TAM: Over 74 million people in North America suffer from OSA, with 56 million undiagnosed, representing significant runway
Clinical differentiation: Growing peer-reviewed evidence positions precision OAT as effective for mild-to-moderate OSA versus CPAP alternatives
Capital strategy: Completed $10M convertible financing in Sept 2023 with goal of achieving cash flow breakeven
Network expansion: Over 4,000 medical providers using ProSomnus devices with 175,000+ units prescribed at IPO disclosure
Named Competitors
CPAP Systems — Continuous Positive Airway Pressure devices - standard OSA treatment but limited patient adherence
Traditional Oral Appliances — Mass-produced mandibular advancement devices for OSA without precision customization
Recent Developments
(December 2022) IPO completion via SPAC merger, began trading on NASDAQ under ticker OSA
(September 2023) Completed $10 million convertible preferred equity offering to optimize operations and pursue cash flow breakeven
(Q1 2023) Record quarterly revenues with 55% YoY growth to $5.8M
Open the full interactive ProSomnus, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.